Literature DB >> 26340519

A novel retinal biomarker for Parkinson's disease: Quantifying the foveal pit with optical coherence tomography.

Samantha Slotnick1,2, Yin Ding3, Sofya Glazman4, Mary Durbin5, Shahnaz Miri6, Ivan Selesnick3, Jerome Sherman2, Ivan Bodis-Wollner4,7,8.   

Abstract

BACKGROUND: Optical coherence tomography offers a potential biomarker tool in Parkinson's disease (PD). A mathematical model quantifying symmetry, breadth, and depth of the fovea was applied.
METHODS: Nintey-six subjects (72 PD and 24 healthy controls) were included in the study. Macular scans of each eye were obtained on two different optical coherence tomography devices: Cirrus and RTVue.
RESULTS: The variables corresponding to the cardinal gradients of the fovea were the most sensitive indicators of PD for both devices. Principal component analysis distinguished 65% of PD patients from controls on Cirrus, 57% on RTVue.
CONCLUSION: Parkinson's disease shallows the superior/inferior and to a lesser degree nasal-temporal foveal slope. The symmetry, breadth, and depth model fits optical coherence tomography data derived from two different devices, and it is proposed as a diagnostic tool in PD.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; SBD model; foveal pit; optical coherence tomography; principal component analysis

Mesh:

Substances:

Year:  2015        PMID: 26340519     DOI: 10.1002/mds.26411

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.

Authors:  Isabel Ortuño-Lizarán; Thomas G Beach; Geidy E Serrano; Douglas G Walker; Charles H Adler; Nicolás Cuenca
Journal:  Mov Disord       Date:  2018-05-08       Impact factor: 10.338

2.  Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases.

Authors:  Ane Murueta-Goyena; Rocío Del Pino; Paula Reyero; Marta Galdós; Begoña Arana; Olaia Lucas-Jiménez; Marian Acera; Beatriz Tijero; Naroa Ibarretxe-Bilbao; Natalia Ojeda; Javier Peña; Jesús Cortés; Juan Carlos Gómez-Esteban; Iñigo Gabilondo
Journal:  Mov Disord       Date:  2019-05-28       Impact factor: 10.338

3.  Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's Disease.

Authors:  Atsuro Uchida; Jagan A Pillai; Robert Bermel; Aaron Bonner-Jackson; Alexander Rae-Grant; Hubert Fernandez; James Bena; Stephen E Jones; James B Leverenz; Sunil K Srivastava; Justis P Ehlers
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

Review 4.  Diagnostic biomarkers for Parkinson's disease at a glance: where are we?

Authors:  Ilaria Cova; Alberto Priori
Journal:  J Neural Transm (Vienna)       Date:  2018-08-25       Impact factor: 3.575

5.  Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.

Authors:  Gianluca Trifirò; Ilaria Marcianò; Paola M Cutroneo; Edoardo Spina; Eliana Mirabelli; Costantino J Trombetta; Francesca Morgante
Journal:  Front Pharmacol       Date:  2018-06-08       Impact factor: 5.810

6.  Circumpapillary Retinal Nerve Fiber Layer OCT Imaging in a Parkinson's Disease Cohort-A Multidisciplinary Approach in a Clinical Research Hospital.

Authors:  Vlad-Ioan Suciu; Corina-Iuliana Suciu; Simona-Delia Nicoară; Lăcrămioara Perju-Dumbravă
Journal:  J Pers Med       Date:  2022-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.